MagnetisMM-5

Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma (MAGNETISMM-5)

Arms / Cohorts

Part 2, Arm A:Experimental Arm A: Elranatamab

Accepting patients

Part 2, Arm B:Experimental Arm B: Elranatamab and Daratumumab

Accepting patients

Part 2, Arm C:Arm C: Daratumumab, Pomalidomide and Dexamethasone

Accepting patients

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 850-0650

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.